Crash Course Compliance: Preparing for FDA’s “Return to Normalcy”

Related Practices

Related Industries

Attorneys & Professionals

As companies have adapted their operations to the realities of the COVID-19 pandemic, many have found themselves navigating U.S. drug and device law for the first time.  So far, this process has been significantly simplified by regulatory waivers and emergency use authorizations (EUA), but with the current public health emergency declaration scheduled to expire on October 23, 2020, now is the time to reassess your company’s FDA compliance.  Join Vorys attorneys Jolie Havens and Mairi Mull as they discuss where to start and what to consider in this webinar briefing.

Click here to register for this complimentary webinar.